Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:23844.

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

Shun-Ichiro Kageyama _, Keiji Nihei, Katsuyuki Karasawa, Takeshi Sawada, Fumiaki Koizumi, Shigeo Yamaguchi, Shunsuke Kato, Hidehiro Hojo, Atsuhi Motegi, Katsuya Tsuchihara and Tetsuo Akimoto

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:19368-19378. https://doi.org/10.18632/oncotarget.25053

Metrics: PDF 1592 views  |   HTML 1182 views  |   ?  


Abstract

Shun-ichiro Kageyama1, Keiji Nihei1, Katsuyuki Karasawa1, Takeshi Sawada1, Fumiaki Koizumi1, Shigeo Yamaguchi1, Shunsuke Kato1, Hidehiro Hojo1, Atsuhi Motegi1, Katsuya Tsuchihara1 and Tetsuo Akimoto1

1National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan

Correspondence to:

Shun-ichiro Kageyama, email: skageyam@east.ncc.go.jp

Keywords: tumoral cell-free DNA; radiotherapy; NSCLC; tumor-specific mutations; digital PCR

Received: November 21, 2017     Accepted: March 21, 2018     Published: April 10, 2018

ABSTRACT

We investigated the plasma levels of tumor-specific cell-free DNA (cfDNA) in 17 stage I–II (early) and IV (advanced) non-small cell lung cancer (NSCLC) patients who underwent radiotherapy. Digital polymerase chain reaction (PCR) and targeted sequencing showed that total and tumor-specific cfDNA levels increased in response to radiotherapy in both early- and advanced-stage NSCLC patients. We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure. In conclusion, our study demonstrates that radiotherapy increases tumoral cfDNA levels in the plasma and shows potential to serve as an indicator for diagnosing drug-resistant tumor-related gene mutations in early-stage NSCLC patients or those undergoing molecular targeted therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25053